Prevalence_NN
of_IN
aneuploidy_NN
,_,
overexpressed_JJ
ER_NN
,_,
and_CC
overexpressed_JJ
EGFR_NN
in_IN
random_JJ
breast_NN
aspirates_NNS
of_IN
women_NNS
at_IN
high_JJ
and_CC
low_JJ
risk_NN
for_IN
breast_NN
cancer_NN
._.

Breast_NN
tissue_NN
biomarkers_NNS
which_WDT
accurately_RB
predict_VBP
breast_NN
cancer_NN
development_NN
within_IN
a_DT
10_CD
year_NN
period_NN
in_IN
high_JJ
risk_NN
women_NNS
are_VBP
needed_VBN
but_CC
currently_RB
not_RB
available_JJ
._.

We_PRP
initiated_VBD
this_DT
study_NN
to_TO
determine_VB
1_LS
-RRB-_-RRB-
the_DT
prevalence_NN
of_IN
one_CD
or_CC
more_JJR
breast_NN
tissue_NN
abnormalities_NNS
in_IN
a_DT
group_NN
of_IN
women_NNS
at_IN
high_JJ
risk_NN
for_IN
breast_NN
cancer_NN
,_,
and_CC
2_LS
-RRB-_-RRB-
if_IN
the_DT
prevalence_NN
of_IN
biomarker_NN
abnormalities_NNS
is_VBZ
greater_JJR
in_IN
high_JJ
risk_NN
than_IN
in_IN
low_JJ
risk_NN
women_NNS
._.

Eligible_JJ
high_JJ
risk_NN
women_NNS
were_VBD
those_DT
with_IN
a_DT
first_JJ
degree_NN
relative_JJ
with_IN
breast_NN
cancer_NN
,_,
prior_JJ
breast_NN
cancer_NN
,_,
or_CC
precancerous_JJ
mastopathy_NN
._.

Low_JJ
risk_NN
women_NNS
were_VBD
those_DT
without_IN
these_DT
or_CC
other_JJ
major_JJ
identifiable_JJ
risk_NN
factors_NNS
._.

Ductal_JJ
cells_NNS
were_VBD
obtained_VBN
via_IN
random_JJ
fine_JJ
needle_NN
aspirations_NNS
and_CC
cytologically_RB
classified_VBN
._.

Biomarkers_NNS
included_VBD
DNA_NN
ploidy_NN
,_,
estrogen_NN
receptor_NN
-LRB-_-LRB-
ER_NN
-RRB-_-RRB-
,_,
and_CC
epidermal_JJ
growth_NN
factor_NN
receptor_NN
-LRB-_-LRB-
EGFR_NN
-RRB-_-RRB-
._.

The_DT
prevalence_NN
of_IN
DNA_NN
aneuploidy_NN
was_VBD
30_CD
%_NN
,_,
overexpression_NN
of_IN
ER_NN
10_CD
%_NN
,_,
and_CC
overexpression_NN
of_IN
EGFR_NN
35_CD
%_NN
,_,
in_IN
the_DT
206_CD
high_JJ
risk_NN
women_NNS
whose_WP$
median_JJ
10_CD
year_NN
Gail_NN
risk_NN
-LRB-_-LRB-
projected_NN
probability_NN
-RRB-_-RRB-
of_IN
developing_NN
breast_NN
cancer_NN
was_VBD
4.5_CD
%_NN
._.

The_DT
prevalence_NN
of_IN
aneuploidy_NN
and_CC
overexpressed_JJ
EGFR_NN
was_VBD
significantly_RB
higher_JJR
in_IN
the_DT
high_JJ
risk_NN
women_NNS
than_IN
in_IN
the_DT
25_CD
low_JJ
risk_NN
controls_NNS
-LRB-_-LRB-
p_NN
&lt;_JJR
0.002_CD
-RRB-_-RRB-
,_,
whose_WP$
median_JJ
10_CD
year_NN
Gail_NN
risk_NN
was_VBD
0.7_CD
%_NN
._.

The_DT
difference_NN
in_IN
the_DT
prevalence_NN
of_IN
ER_NN
overexpression_NN
between_IN
high_JJ
and_CC
low_JJ
risk_NN
groups_NNS
was_VBD
not_RB
statistically_RB
significant_JJ
-LRB-_-LRB-
p_NN
=_JJ
0.095_CD
-RRB-_-RRB-
._.

This_DT
may_MD
be_VB
due_JJ
to_TO
the_DT
low_JJ
prevalence_NN
of_IN
overexpressed_JJ
ER_NN
and_CC
the_DT
small_JJ
number_NN
of_IN
controls_NNS
._.

A_DT
significant_JJ
difference_NN
was_VBD
noted_VBN
in_IN
the_DT
prevalence_NN
of_IN
one_CD
or_CC
more_JJR
abnormal_JJ
biomarkers_NNS
between_IN
the_DT
high_JJ
risk_NN
and_CC
low_JJ
risk_NN
women_NNS
-LRB-_-LRB-
p_NN
&lt;_JJR
0.001_CD
-RRB-_-RRB-
._.

A_DT
large_JJ
prospective_JJ
trial_NN
is_VBZ
needed_VBN
to_TO
determine_VB
if_IN
one_CD
or_CC
more_JJR
of_IN
these_DT
biomarkers_NNS
,_,
is_VBZ
predictive_JJ
of_IN
breast_NN
cancer_NN
development_NN
._.

